Previous close | 22.14 |
Open | 22.18 |
Bid | 22.12 x 0 |
Ask | 22.13 x 0 |
Day's range | 21.82 - 22.26 |
52-week range | 20.38 - 32.08 |
Volume | |
Avg. volume | 8,864,105 |
Market cap | 53.739B |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | 29.51 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.42 (1.90%) |
Ex-dividend date | 09 Aug 2023 |
1y target est | N/A |
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).